Document is current

Article History

Received: 6 December 2023

Accepted: 9 July 2024

First Online: 19 July 2024

Competing interests

: A.C., A.Datta, M.Z., S.R., Y.A., and Y.S. are employed by and hold stock options in Bristol Myers Squibb. A. Diab has received honoraria from Array BioPharma; consulting or advisory fees from Nektar Therapeutics, CureVac, Celgene, Idera, Memgen Therapeutics, Regeneron, and CytomX Therapeutics; meeting attendance support from Nektar Therapeutics; institutional research funding from Nektar Therapeutics, Bristol Myers Squibb, Idera, Celgene, Pfizer, Apexigen, and Lytix Biopharma. A.J.M.V.D.E. has received research grants from Bristol Myers Squibb, Idera, Sanofi, TEVA; consulting fees from Amgen, Bristol Myers Squibb, Ipsen, Merck, MSD Oncology, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi; meeting attendance support from MSD Oncology, Pfizer, Pierre Fabre, Roche, Sanofi. B.C. has received research grants from Bristol Myers Squibb. A.S. has received consulting fees from Bristol Myers Squibb, Merck; research grants from Alkermes, ALX Oncology, Amgen, Array Biopharma/Pfizer AstraZeneca/Medimmune, Bayer, Bristol Myers Squibb, Genentech, GSK, Janssen Oncology/Johnson & Johnson, Merck, Northern Biologics, Novartis, NuBiyota, Oncorus, Regeneron, Roche, Seagen, Servier, Surface Oncology, Symphogen, Treadwell. C.L. has received research grants from Bristol Myers Squibb, Roche; consulting fees from Amgen, Bristol Myers Squibb, Merck Serono, MSD, Novartis, Pierre Fabre, Roche, Sanofi; speaker honoraria from Amgen, Bristol Myers Squibb, Incyte, MSD, Novartis, Pfizer, Pierre Fabre, Roche; meeting attendance support from Bristol Myers Squibb, MSD, Novartis, Pierre Fabre, Sanofi; has participated in advisory boards for InflaRx; is a board member for Avants Medical Systems, Bristol Myers Squibb, Jazz Pharmaceuticals, MSD, Novartis, Pierre Fabre and Sanofi. C.P. has received speaker honoraria from Bristol Myers Squibb, Merck, Novartis, Zodiac; has participated in advisory boards for Novartis, Zodiac. E.M.C. has received consulting fees from Bristol Myers Squibb, MSD, Novartis, Pierre Fabre; speaker honoraria from Bristol Myers Squibb, Novartis, Pierre Fabre; expert testimony payments from Bristol Myers Squibb, MSD, Novartis; meeting attendance support from Bristol Myers Squibb, Novartis, Pierre Fabre; has participated in advisory boards for Bristol Myers Squibb, MSD, Sanofi; is in a leadership role in GEM (Grupo Español de Melanoma). G.V.L. has participated in advisory boards and has received consulting fees from Agenus, Amgen, Array Biopharma, Boehringer Ingelheim International, Bristol Myers Squibb, Evaxion Biotech A/S, Hexal AG (Sandoz Company), Highlight Therapeutics S.L, Innovent Biologics USA, MSD, Novartis, OncoSec Medical Australia, Pierre Fabre, Provectus Australia, Qbiotics Group, Regeneron Pharmaceuticals; speaker honoraria from Bristol Myers Squibb, Pierre Fabre. H.G. has participated in advisory boards and has been an invited speaker for Bristol Myers Squibb, MSD, Pierre Fabre, Sanofi; has been an invited speaker for Novartis; has been local principal investigator for Amgen, Bayer, Bristol Myers Squibb, Iovance, MSD, Replimune; has been a steering committee member for Amgen and Replimune; has received research grants from Bristol Myers Squibb, Lilly, Pfizer, Pierre Fabre. M.T. has received research grants from Bristol Myers Squibb, Exelixis, Merck, Pfizer; consulting fees from Array Biopharma, Bayer, Cascade Prodrug, Immune-Onc, Incyte, Merck, Novartis, Pfizer, Regeneron, Sanofi/Genzyme; speaker honoraria from Blueprint Medicines, Bristol Myers Squibb, Eisai, Merck; has participated in an advisory board for Oncosec. N.I.K. has received research grants from Celgene, GSK, HUYA, Merck, Modulation Therapeutics, Novartis, Regeneron, Replimune; has participated in advisory boards and has received consulting fees from Bristol Myers Squibb, Castle, Genzyme, Instil Bio, Iovance, Jounce, Merck, Nektar Therapeutics, Novartis, Regeneron, Replimune; meeting attendance support from Regeneron; has been a member of a data safety monitoring committee for AstraZeneca, Incyte; has been a steering committee member for Bristol Myers Squibb, Nektar Therapeutics, NCCN (via Pfizer), Regeneron, Replimune; holds stock for Amarin Corporation, Asensus Surgical, Bellicum Pharmaceuticals, Mazor Robotics. S.S. has received research grants from AstraZeneca, Genentech, MSD, Novartis/Advanced Accelerators Applications, Pfizer; speaker honoraria from AstraZeneca, Bristol Myers Squibb, Janssen, MSD; is chair of a data monitoring committee for Novartis. T.M. has participated in advisory boards and has received consulting fees from AstraZeneca, Bristol Myers Squibb, Esai, GSK, MSD, Novartis; has received speaker honoraria from AstraZeneca; meeting attendance support from AstraZeneca, Bristol Myers Squibb. G.D. and G.Q. declare no competing interests.